The following table reconciles the net income and the weighted average common shares outstanding used in the computations of basic and diluted earnings per common share:


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands, except per share amounts)	2026		2025		2026		2025
Net income	$	163,376	$	164,215	$	524,889	$	534,987

Basic weighted average shares outstanding	88,964		97,400		91,156		100,086
Dilutive effect of nonvested shares	810		1,119		738		1,069
Diluted weighted average shares outstanding	89,774		98,519		91,894		101,155

Basic earnings per share	$	1.84	$	1.69	$	5.76	$	5.35
Diluted earnings per share	$	1.82	$	1.67	$	5.71	$	5.29

There were 13,351 and 5,847 antidilutive shares for the three months ended September 30, 2026 and 2025, respectively, and 37,247 and 47,223 antidilutive shares for the nine months ended September 30, 2026 and 2025, respectively.

Nonvested performance-based share awards are considered contingently issuable for purposes of the EPS calculation. The 2026, 2025 and 2024 performance-based share awards vest based upon our compounded annual book value per share growth percentage and relative total shareholder return during a three-year performance period. The following table summarizes the performance-based shares issuable if the reporting date was the end of the contingency period:


	2026 Performance-Based Grants		2025 Performance-Based Grants		2024 Performance-Based Grants		2023 Performance-Based Grants
Reporting Date	Percent Issuable Relative to Target	As a Percent of Shares Issued	Percent Issuable Relative to Target	As a Percent of Shares Issued	Percent Issuable Relative to Target	As a Percent of Shares Issued	Percent Issuable Relative to Target	As a Percent of Shares Issued
September 30, 2026	133%	66.5%	187%	93.5%	116%	58%	(1)	(1)
September 30, 2025			200%	100%	134%	67%	197%	98.5%